Jeffery Errington
Founder at Demuris Ltd.
Profile
Jeffery Errington is the founder of Demuris Ltd.
(founded in 2007) and serves as the Chief Executive Officer & Director.
Dr. Errington is also the founder of Prolysis Ltd.
Dr. Errington's former job positions include being an Independent Non-Executive Director at Biota Holdings Pty Ltd.
(2010-2013), Director-Centre for Bacterial Cell Biology at The University of Newcastle (2012), Non-Executive Director at Aviragen Therapeutics, Inc. (2012-2013), and Professor-Microbiology at the University of Oxford.
Dr. Errington's education includes a graduate degree from the University of Oxford and an undergraduate degree from The University of Newcastle.
Jeffery Errington active positions
| Companies | Position | Start |
|---|---|---|
Demuris Ltd.
 Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Founder | 2007-05-21 |
Former positions of Jeffery Errington
| Companies | Position | End |
|---|---|---|
| BIOTA HOLDINGS LTD. | Director/Board Member | 2013-08-11 |
Aviragen Therapeutics, Inc.
 Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Director/Board Member | 2013-08-11 |
| The University of Newcastle | Corporate Officer/Principal | - |
| University of Oxford | Corporate Officer/Principal | - |
Prolysis Ltd.
 Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Founder | - |
Training of Jeffery Errington
| University of Oxford | Graduate Degree |
| The University of Newcastle | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Biota Holdings Pty Ltd.
 Biota Holdings Pty Ltd. Pharmaceuticals: MajorHealth Technology Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia. | Health Technology |
Prolysis Ltd.
Prolysis Ltd. Pharmaceuticals: MajorHealth Technology Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK. | Health Technology |
Demuris Ltd.
Demuris Ltd. Medical DistributorsDistribution Services Demuris Ltd. develops portfolio of novel antibiotics. The firm is an antibiotic discovery company, which provides technologies of genome engineering, natural product sourcing, and target-based screening. It's products include broad spectrum, gram positive, tuberculosis, anti-fungal, and anti-cancer programs. The company was founded by Jeffery Errington on May 22, 2007 and is headquartered in Newcastle-upon-Tyne, the United Kingdom. | Distribution Services |
Aviragen Therapeutics, Inc.
Aviragen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections. Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA. | Health Technology |
- Stock Market
- Insiders
- Jeffery Errington
